Payer+Provider's Health System Review
May 9, 2022
The AI-powered company is unlocking the hidden healing potential of plants by finding active compounds that could target specific conditions. Next up: diabetes and sleep disorders.
October 1, 2021
The Boston-based neuroscience startup raised $70 million to turn its patented molecules based on classic psychedelic drugs into medicine.
September 25, 2020
If approved, MindMed could become the second psychedelic drug development company listed on Nasdaq.